GLTO - Galecto, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
11.32 0.45 (3.98%)	---	---	---	-0.51 (-4.51%)	0.94 (8.68%)	0.01 (0.09%)	-0.44 (-3.91%)

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -2.6
Diluted EPS:: -2.6
Basic P/E:: -4.5269
Diluted P/E:: -4.5269
RSI(14) 1m:: 100.0
VWAP:: 11.67
RVol:: 0.0205

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	11.77 +0.13 (+1.16%)	Oct 15 15:59
1m	Price increase 1m	11.72 +0.18 (+1.52%)	Oct 15 14:48
1m	Price decrease 1m	11.4 -0.14 (-1.21%)	Oct 15 14:20
1m	Price decrease 1m	11.94 -0.13 (-1.08%)	Oct 15 11:02
1m	Price increase 1m	12.17 +0.25 (+2.1%)	Oct 15 10:49